HRP20210398T1 - Režimi doziranja za liječenje pompeove bolesti - Google Patents
Režimi doziranja za liječenje pompeove bolesti Download PDFInfo
- Publication number
- HRP20210398T1 HRP20210398T1 HRP20210398TT HRP20210398T HRP20210398T1 HR P20210398 T1 HRP20210398 T1 HR P20210398T1 HR P20210398T T HRP20210398T T HR P20210398TT HR P20210398 T HRP20210398 T HR P20210398T HR P20210398 T1 HRP20210398 T1 HR P20210398T1
- Authority
- HR
- Croatia
- Prior art keywords
- dnj
- pharmaceutically acceptable
- acceptable salt
- replacement therapy
- human recombinant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642311P | 2012-05-03 | 2012-05-03 | |
| US201261664011P | 2012-06-25 | 2012-06-25 | |
| US201261697179P | 2012-09-05 | 2012-09-05 | |
| US201361749234P | 2013-01-04 | 2013-01-04 | |
| US201361749132P | 2013-01-04 | 2013-01-04 | |
| PCT/US2013/039215 WO2013166249A1 (en) | 2012-05-03 | 2013-05-02 | Dosing regimens for the treatment of pompe disease |
| EP13785028.5A EP2844279B1 (en) | 2012-05-03 | 2013-05-02 | Dosing regimens for the treatment of pompe disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210398T1 true HRP20210398T1 (hr) | 2021-05-28 |
Family
ID=49514881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210398TT HRP20210398T1 (hr) | 2012-05-03 | 2013-05-02 | Režimi doziranja za liječenje pompeove bolesti |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20150086530A1 (https=) |
| EP (3) | EP3871688B1 (https=) |
| JP (6) | JP6381521B2 (https=) |
| CY (1) | CY1124135T1 (https=) |
| DK (1) | DK2844279T3 (https=) |
| ES (2) | ES2859761T3 (https=) |
| HR (1) | HRP20210398T1 (https=) |
| HU (1) | HUE053565T2 (https=) |
| LT (1) | LT2844279T (https=) |
| PL (1) | PL2844279T3 (https=) |
| PT (1) | PT2844279T (https=) |
| RS (1) | RS61598B1 (https=) |
| SI (1) | SI2844279T1 (https=) |
| SM (1) | SMT202100136T1 (https=) |
| WO (1) | WO2013166249A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10449193B2 (en) | 2011-06-03 | 2019-10-22 | Signpath Pharma Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies |
| US8753674B2 (en) | 2011-06-03 | 2014-06-17 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current |
| US10349884B2 (en) | 2011-06-03 | 2019-07-16 | Sighpath Pharma Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel |
| US10117881B2 (en) | 2011-06-03 | 2018-11-06 | Signpath Pharma, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies |
| US12004868B2 (en) | 2011-06-03 | 2024-06-11 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel |
| US10532045B2 (en) | 2013-12-18 | 2020-01-14 | Signpath Pharma, Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel |
| US10238602B2 (en) | 2011-06-03 | 2019-03-26 | Signpath Pharma, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies |
| SMT202100136T1 (it) * | 2012-05-03 | 2021-05-07 | Amicus Therapeutics Inc | Regimi posologici per il trattamento della malattia di pompe |
| US9675627B2 (en) * | 2014-04-14 | 2017-06-13 | Amicus Therapeutics, Inc. | Dosing regimens for treating and/or preventing cerebral amyloidoses |
| AU2015269699B2 (en) | 2014-06-03 | 2020-08-13 | Avanti Polar Lipids, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies |
| CN114540327B (zh) | 2014-09-30 | 2026-03-24 | 阿米库斯治疗学公司 | 具有增强的碳水化合物的高强度酸性α-葡糖苷酶 |
| TW202417620A (zh) * | 2014-09-30 | 2024-05-01 | 美商阿米庫斯醫療股份有限公司 | 高效經修飾之酸性α-葡萄糖苷酶及其製造與使用方法 |
| KR20250007693A (ko) | 2015-12-30 | 2025-01-14 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
| HRP20231465T1 (hr) | 2015-12-30 | 2024-03-01 | Amicus Therapeutics, Inc. | Poboljšana kisela alfa-glukozidaza za liječenje pompeove bolesti |
| CA3019354A1 (en) | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Method for selection of high m6p recombinant proteins |
| AU2017239641A1 (en) | 2016-03-30 | 2018-10-18 | Amicus Therapeutics, Inc. | Formulations comprising recombinant acid alpha-glucosidase |
| AU2017257496B2 (en) | 2016-04-27 | 2020-05-07 | Signpath Pharma, Inc. | Prevention of drug-induced atrio-ventricular block |
| US11944628B2 (en) | 2017-05-12 | 2024-04-02 | Duke University | Methods for the use of low-dose immune modulators transiently for treating patients undergoing protein replacement therapy |
| SMT202300187T1 (it) | 2017-05-15 | 2023-07-20 | Amicus Therapeutics Inc | Alfa-glucosidasi acida umana ricombinante |
| WO2022227287A1 (zh) * | 2021-04-25 | 2022-11-03 | 中南大学 | Dnj及其衍生物在制备预防和/或治疗肺动脉高压药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| AU2001269923A1 (en) | 2000-06-19 | 2002-01-02 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| WO2002087510A2 (en) | 2001-04-30 | 2002-11-07 | Symbiontics, Inc. | Subcellular targeting of therapeutic proteins |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| WO2003086452A2 (en) | 2002-04-05 | 2003-10-23 | Genzyme Corporation | Methods of enhancing lysosomal storage disease therapy |
| HUE036449T2 (hu) | 2003-06-24 | 2018-07-30 | Genzyme Corp | Új béta-aktin és RPS21 promóterek és alkalmazásaik |
| US20080014188A1 (en) | 2004-02-06 | 2008-01-17 | Zankel Todd C | Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof |
| CA2553955C (en) | 2004-02-10 | 2012-08-28 | Zystor Therapeutics, Inc. | Acid alpha-glucosidase and fragments thereof |
| EP3782655A1 (en) * | 2005-05-17 | 2021-02-24 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| MX2009011473A (es) * | 2007-04-26 | 2010-01-18 | Amicus Therapeutics Inc | Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas. |
| WO2010056746A1 (en) | 2008-11-11 | 2010-05-20 | Amicus Therapeutics, Inc. | Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease |
| SMT202100136T1 (it) * | 2012-05-03 | 2021-05-07 | Amicus Therapeutics Inc | Regimi posologici per il trattamento della malattia di pompe |
-
2013
- 2013-05-02 SM SM20210136T patent/SMT202100136T1/it unknown
- 2013-05-02 US US14/398,210 patent/US20150086530A1/en active Pending
- 2013-05-02 SI SI201331858T patent/SI2844279T1/sl unknown
- 2013-05-02 PL PL13785028T patent/PL2844279T3/pl unknown
- 2013-05-02 EP EP20207542.0A patent/EP3871688B1/en active Active
- 2013-05-02 ES ES13785028T patent/ES2859761T3/es active Active
- 2013-05-02 JP JP2015510446A patent/JP6381521B2/ja active Active
- 2013-05-02 RS RS20210295A patent/RS61598B1/sr unknown
- 2013-05-02 PT PT137850285T patent/PT2844279T/pt unknown
- 2013-05-02 HU HUE13785028A patent/HUE053565T2/hu unknown
- 2013-05-02 EP EP24161179.7A patent/EP4397364A3/en active Pending
- 2013-05-02 ES ES20207542T patent/ES2980828T3/es active Active
- 2013-05-02 DK DK13785028.5T patent/DK2844279T3/da active
- 2013-05-02 HR HRP20210398TT patent/HRP20210398T1/hr unknown
- 2013-05-02 WO PCT/US2013/039215 patent/WO2013166249A1/en not_active Ceased
- 2013-05-02 EP EP13785028.5A patent/EP2844279B1/en active Active
- 2013-05-02 LT LTEP13785028.5T patent/LT2844279T/lt unknown
-
2018
- 2018-01-19 JP JP2018007672A patent/JP6612370B2/ja active Active
-
2019
- 2019-10-29 JP JP2019196583A patent/JP6876111B2/ja active Active
-
2021
- 2021-01-27 JP JP2021010931A patent/JP7046241B2/ja active Active
- 2021-03-09 CY CY20211100202T patent/CY1124135T1/el unknown
-
2022
- 2022-03-22 JP JP2022044812A patent/JP2022101544A/ja not_active Withdrawn
-
2024
- 2024-03-07 JP JP2024034587A patent/JP2024081667A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022101544A (ja) | 2022-07-06 |
| PT2844279T (pt) | 2021-03-11 |
| JP6612370B2 (ja) | 2019-11-27 |
| JP2018109003A (ja) | 2018-07-12 |
| LT2844279T (lt) | 2021-03-25 |
| JP2020045346A (ja) | 2020-03-26 |
| SMT202100136T1 (it) | 2021-05-07 |
| ES2859761T3 (es) | 2021-10-04 |
| EP2844279A1 (en) | 2015-03-11 |
| JP2024081667A (ja) | 2024-06-18 |
| ES2980828T3 (es) | 2024-10-03 |
| US20150086530A1 (en) | 2015-03-26 |
| JP6876111B2 (ja) | 2021-05-26 |
| EP2844279B1 (en) | 2020-12-09 |
| EP2844279A4 (en) | 2015-12-16 |
| SI2844279T1 (sl) | 2021-04-30 |
| CY1124135T1 (el) | 2022-05-27 |
| PL2844279T3 (pl) | 2021-08-16 |
| EP3871688B1 (en) | 2024-03-06 |
| EP3871688A1 (en) | 2021-09-01 |
| JP2015519329A (ja) | 2015-07-09 |
| WO2013166249A1 (en) | 2013-11-07 |
| HUE053565T2 (hu) | 2021-07-28 |
| DK2844279T3 (da) | 2021-03-15 |
| JP6381521B2 (ja) | 2018-08-29 |
| EP4397364A3 (en) | 2024-09-04 |
| RS61598B1 (sr) | 2021-04-29 |
| EP4397364A2 (en) | 2024-07-10 |
| JP2021088561A (ja) | 2021-06-10 |
| JP7046241B2 (ja) | 2022-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210398T1 (hr) | Režimi doziranja za liječenje pompeove bolesti | |
| JP2015519329A5 (https=) | ||
| JP2020033360A5 (https=) | ||
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| HRP20251310T1 (hr) | Enzimsko-nadomjesna terapija s povezivanjem doze za liječenje deficita kisele sfingomijelinaze | |
| ME02477B (me) | Genz 112638 za lečenje gošeove ili fabrijeve bolesti u kombinacionoj terapiji | |
| HRP20191162T1 (hr) | Postupci liječenja ankilozantnog spondilitisa uporabom anti-il-17 protutijela | |
| HRP20180301T1 (hr) | Postupci liječenja psorijaze uporabom il-17 antagonista | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
| JP2018528252A5 (https=) | ||
| BR112012020236A2 (pt) | uso de um composto com atividade antagonística de ep4 ou um sal farmaceuticamente aceitável do mesmo, uso de um composto da fórmula (i), (ii), (iii), (iv), (va) ou (vb), ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e método para o tratamento de doenças mediadas por il-23 em um sujeito animal, incluindo um sujeito mamífero | |
| JP2014528901A5 (https=) | ||
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| HRP20241454T1 (hr) | Migalastat za upotrebu u postupcima liječenja fabrijeve bolesti kod pacijenata koji imaju mutaciju u gla genu | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| JP2014513722A5 (https=) | ||
| HRP20221366T1 (hr) | Postupci poboljšanja i/ili stabilizacije srčane funkcije kod bolesnika s fabrijevom bolešću | |
| HRP20180468T1 (hr) | Novi derivat analoga inzulina | |
| HRP20240025T1 (hr) | Liječenje bolesnika s klasičnom fabrijevom bolešću migalastatom | |
| AR080096A1 (es) | Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib | |
| AR088204A1 (es) | Medicamentos para el tratamiento de la rinitis alergica que comprenden un antagonista de pgd2 y un antagonista de histamina |